二丙酸倍氯米松(Beclometasone Dipropionate) - 药物靶点：GR_在研适应症：季节性过敏性鼻炎，血管舒缩性鼻炎，哮喘_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione、9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate、9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate

+ [49]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

免疫系统疾病感染耳鼻咽喉疾病+ [2]

在研适应症

季节性过敏性鼻炎血管舒缩性鼻炎哮喘+ [2]

非在研适应症

急性移植物抗宿主病急性鼻窦炎支气管高反应性+ [13]

原研机构

在研机构

+ [4]

非在研机构

Schering Corp.

CHIESI Farmaceutici SpAAllergan UC

+ [2]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1976-05-12),

哮喘过敏性鼻炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C28H37ClO7

InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N

CAS号5534-09-8

关联

174

项与二丙酸倍氯米松相关的临床试验

CTR20243802

/ CompletedN/A

吸入用丙酸倍氯米松混悬液单次给药、随机、开放、两周期、双交叉、空腹状态下的生物等效性研究

主要研究目的：以Chiesi Farmaceutici S.p.A.持证的吸入用丙酸倍氯米松混悬液（规格：2 ml: 0.8 mg，商品名：宝丽亚®）为参比制剂，以南京力成药业有限公司研发的吸入用丙酸倍氯米松混悬液（规格：2 ml: 0.8 mg）为受试制剂，通过单中心、随机、开放、两序列、两周期、双交叉临床研究来评价两种制剂在空腹状态下的人体生物等效性。次要研究目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

开始日期2024-11-10

申办/合作机构

南京力成药业有限公司

CTR20242753

/ CompletedN/A

吸入用丙酸倍氯米松混悬液单次给药、随机、开放、两周期、双交叉、空腹状态下的生物等效性研究

以Chiesi Farmaceutici S.p.A.持证的吸入用丙酸倍氯米松混悬液（规格：2 ml: 0.8 mg，商品名：宝丽亚®）为参比制剂，以南京力成药业有限公司研发的吸入用丙酸倍氯米松混悬液（规格：2 ml: 0.8 mg）为受试制剂，通过单中心、随机、开放、两序列、两周期、双交叉临床研究来评价两种制剂在空腹状态下的人体生物等效性。次要研究目的：观察受试制剂和参比制剂的安全性

开始日期2024-07-26

申办/合作机构

南京力成药业有限公司

NCT06482294

/ Active, not recruiting临床2期IIT

CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma

Single-center, interventional, open-label, randomized phase II study aimed at describing the changes in airway inflammation at the onset of asthma symptoms that lead to the use of rapid acting bronchodilator (RABD) as a rescue medication in a mild to moderate asthma population. The study will assess whether there are differences in the airway inflammation profile in patients using a reliever medication containing ICS (anti-inflammatory rescue strategy) compared to a reliever medication containing only a bronchodilator for symptom relief (Non anti-inflammatory rescue strategy).

开始日期2024-06-18

申办/合作机构-

100 项与二丙酸倍氯米松相关的临床结果

登录后查看更多信息

100 项与二丙酸倍氯米松相关的转化医学

登录后查看更多信息

100 项与二丙酸倍氯米松相关的专利（医药）

登录后查看更多信息

4,259

项与二丙酸倍氯米松相关的文献（医药）

2025-06-01·PULMONARY PHARMACOLOGY & THERAPEUTICS

Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler

Article

作者: Pacchetti, Ilaria ; Mathews, Kusum S ; Van Leuven, Katrin ; Martini, Matteo ; Rony, François ; Contursi, Cristina ; Poli, Gianluigi ; Viganò, Luca Vittorio ; Pittelli, Maria Gloria ; Calabrò, Emanuele Rocco

INTRODUCTION:

Use of high global warming potential propellants (e.g., HFA-134a) for pressurised metered-dose inhalers (pMDIs) is being phased down. Beclometasone dipropionate (BDP) is approved for the treatment of asthma in several countries via an HFA-134a propellant pMDI. This is being reformulated using the low global warming potential propellant HFA-152a. Two studies compared BDP pharmacokinetics delivered via pMDI using HFA-152a vs HFA-134a.

METHODS:

Both studies (N=71/study) were single-dose (four inhalations of BDP), randomised, double-blind, crossover (Study 1, four-way; Study 2, two-way), in healthy volunteers. In Study 1, subjects inhaled BDP via HFA-134a pMDI in two periods (200 μg/actuation in one period, 100 μg/actuation in the other) and HFA-152a pMDI in the other two (200 or 100 μg/actuation). In Study 2, subjects inhaled BDP 200 μg/actuation via HFA-134a or HFA-152a pMDI using a spacer device. pMDIs containing HFA-152a and HFA-134a were compared in terms of lung availability (BDP comparisons) and total systemic exposure (beclometasone-17-monopropionate comparisons [B17MP; active metabolite of BDP]), with bioequivalence concluded if the 90% confidence intervals (CIs) of the geometric mean ratios of maximum plasma concentration (C_max) and area under the plasma concentration-time curve between time zero and the last quantifiable timepoint (AUC_0-t) were between 80-125%.

RESULTS:

BDP C_max and AUC_0-t were equivalent for the two BDP 200 μg formulations, without (Study 1) and with spacer (Study 2). BDP 100 μg AUC_0-t met the bioequivalence criteria, but the C_max lower 90% CI was marginally below the bioequivalence limit (79.46%). B17MP C_max and AUC_0-t were bioequivalent with both propellants in all three comparisons.

CONCLUSIONS:

Overall, bioequivalence was confirmed of HFA-152a and HFA-134a for BDP 200 μg/actuation, with and without a spacer. Although bioequivalence of the two formulations cannot be formally concluded for BDP 100 μg, the minimal difference suggests the two formulations can be considered therapeutically equivalent.

2025-06-01·Dermatology and Therapy

Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials

Article

作者: Freischläger, Frank ; Pinter, Andreas ; Galván, Jordi

INTRODUCTION:

Individual endpoints from phase 3 trials demonstrated high efficacy and convenience for the calcipotriol/betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology compared to CAL/BDP gel. The objectives are to assess the proportion of best responders to CAL/BDP PAD-cream at weeks 4 and 8 and to identify the super-responders through the patients' key baseline characteristics associated with best response.

METHODS:

This was a post hoc pooled analysis of adult patients with mild-to-moderate psoriasis from two phase 3 trials: MC2-01-C2 (NCT03308799) and MC2-01-C7 (NCT03802344). Patients were randomly assigned (3:1:3) to CAL/BDP PAD-cream, PAD-cream vehicle, or CAL/BDP gel once daily. Best responders at weeks 4 and 8 were defined as patients achieving a restrictive endpoint comprising the combination of Physician's Global Assessment (PGA) controlled disease, modified Psoriasis Area and Severity Index (mPASI) success, and Dermatology Life Quality Index (DLQI) satisfaction. Best response rates were compared between treatments by logistic regression using multiple imputation. A classification and regression tree (CART) based on observed cases identified super-responders through the key baseline characteristics associated with best response among CAL/BDP PAD-cream users. All analyses were based on the modified intention-to-treat (mITT) population.

RESULTS:

The mITT included 551 patients on CAL/BDP PAD-cream, 542 on CAL/BDP gel, and 178 on vehicle. The CAL/BDP PAD-cream group showed a statistically significant higher best response rate compared to CAL/BDP gel at week 4 (10.7% vs 6.1%; p = 0.0048) and week 8 (27.4% vs 16.1%; p < 0.0001), and also compared to vehicle. Among CAL/BDP PAD-cream users, 63.6% of patients with a baseline DLQI < 7 and mPASI < 4.0 achieved best response at week 8 and were considered super-responders.

CONCLUSION:

CAL/BDP PAD-cream demonstrated higher best response rates compared to CAL/BDP gel and vehicle in adults with mild-to-moderate psoriasis. Baseline DLQI and mPASI scores may predict which patients are most likely to achieve best response to CAL/BDP PAD-cream.

TRIALS REGISTRATION:

ClinicalTrials.gov identifiers, NCT03308799 (MC2-01-C2) and NCT03802344 (MC2-01-C7).

2025-05-04·JOURNAL OF ASTHMA

Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: the FEEL study

Article

作者: Patella, Vincenzo ; Van der Deijl, Marielle ; Colloca, Luana ; Topole, Eva ; Blasi, Francesco ; Martini, Matteo ; Bucchioni, Enrica ; Grapin, Frédérique ; D’Amato, Maria ; Geraci, Silvia

OBJECTIVES:

Patient perception of treatment effectiveness is key to optimizing adherence. This is potentially impacted by color, yet no such studies have been conducted in asthma. This study assessed the influence of pink vs. white pressurized metered-dose inhaler (pMDI) actuators on asthma symptoms perception.

METHODS:

In this double-blind, randomized, multicenter, crossover study, adults with moderate-to-severe asthma received extrafine formulation beclomethasone dipropionate/formoterol furoate (BDP/FF) pMDI for a 2-week run-in. During two, 2-week treatment periods they received BDP/FF pMDI, white in one, pink in the other, using an 'authorized deception' approach (patients were told the inhalers contained the same active ingredients, but device characteristics differed). Endpoints included patient-reported asthma symptoms and psychopharmacological aspects (prior to use: did patients expect an improvement; after use: did they think there had been an improvement; both on 100-point visual analog scales [VAS]).

RESULTS:

Of 74 patients analyzed, 72 completed the study. There were no statistically significant differences between inhalers for asthma symptoms, with minimal changes from baseline. Patients were numerically more likely to expect symptoms improvement with the white than pink inhaler (mean VAS 64.5 vs. 60.8). Perceived improvements were lower than expected with both, numerically favoring the pink inhaler (mean VAS 41.1 vs. 44.6); 46.6% believed a change had been made, 51.9% of whom believed this impacted symptoms.

CONCLUSIONS:

Changing inhaler color had no impact on asthma symptoms, but did have a numerical impact on patients' expectations of subsequent treatment effect. This emphasizes the importance of communication between patients and healthcare practitioners when changing inhalers.

91

项与二丙酸倍氯米松相关的新闻（医药）

2025-05-21

·药筛

海思科 1类镇痛新药获批，创健吸入用丙酸倍氯米松混悬液国产第二家

今天的NMPA新批文，有多个品种值得关注！首先是几个新药，比如海思科的镇痛1类新药安瑞克芬注射液获批。这是一款外周kappa阿片受体选择性激动剂，用于治疗腹部手术后的轻、中度疼痛，市场广阔。四环的CDK4/6抑制剂吡洛西利片，用于用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性晚期或转移性乳腺癌成人患者；与氟维司群联合用于既往接受内分泌治疗后出现疾病进展的患者；单药用于既往转移性阶段接受过两种及以上内分泌治疗和一种化疗后出现疾病进展的患者。仿制药方面，重点关注品种有：宜昌人福的氢可酮布洛芬片，国内首家上市。成都硕德药的水合氯醛灌肠剂，国内第二家批文。高难度的吸入用丙酸倍氯米松混悬液，河北创健第二家国产过评。浙江仙琚的黄体酮软胶囊，国产第四家。科伦新增两个重磅粉液双室袋产品：注射用比阿培南/氯化钠注射液和注射用头孢他啶/氯化钠注射液。快速筛选药品，就用摩熵药筛小程序加客服小筛微信，进群获取第一手资讯数据

申请上市

2025-05-11

·米内网

4月21个品种首家过评，12个品种获批新适应症；这个品种原研刚获批同月5家企业抢首仿

摘要abstract2025年4月，10个1类新药、9个改良型新药申请上市，254个品种按新分类仿制申请申报，其中37个品种暂无国内仿制获批，佩玛贝特片、富马酸伏诺拉生片、艾拉莫德片、阿达帕林凝胶等品种仿制企业最多，均有5家；17个存量品种有企业申报一致性评价，其中1个品种为首次申报；4个1类新药首次获批上市，12个品种获批新适应症；21个品种首家过评，其中14个为首仿。创新药品种上市申请情况2025年4月有10个1类新药申请上市，其中化学药有4个，中成药和生物制品各有3个。南京征祥医药的玛硒洛沙韦片在2025年2月首次申报上市，本次报产为新增适应症。其他品种均为首次申报上市。2025年4月创新药上市申请承办情况改良型新药品种上市申请情况2025年4月有9个改良型新药品种的上市申请获CDE承办。江苏天士力帝益药业的PXT3003、施慧达药业集团(吉林)的左氨氯地平比索洛尔片(Ⅰ)和左氨氯地平比索洛尔片(Ⅱ)均属于新复方制剂。国药山西瑞福莱药业和江苏和晨药业的布瑞哌唑口溶膜、Biogen的诺西那生钠注射液均属于新剂型。2025年4月改良型新药上市申请承办情况一致性评价申请情况2025年4月，254个品种按新分类仿制申请获CDE承办，其中37个品种在中国境内暂无仿制药获批。佩玛贝特片、富马酸伏诺拉生片、艾拉莫德片、阿达帕林凝胶等4个品种均有5家企业申报。值得一提的是，佩玛贝特片的原研企业是日本兴和制药，用于治疗高脂血症，并于2025年4月8日在中国获批。原研企业刚获批，随后从4月23日起，南京正大天晴制药、遂成药业、成都倍特药业、广州大光制药、湖南科伦制药等5家企业的仿制申请已陆续获CDE承办。2025年4月一致性评价申请情况(新分类仿制申请)2025年4月，17个存量品种的一致性评价补充申请获CDE承办。盐酸左西替利嗪颗粒首次有企业按补充申请申报。2025年4月一致性评价申请情况(存量品种)获批情况2025年4月有4款1类新药首次获批上市：波哌达可基注射液(上海信致医药科技)、卡匹色替片(阿斯利康)、小儿牛黄退热贴膏(健民药业集团)、依若奇单抗注射液(中山康方生物医药)。此外，12个品种获批新适应症。 169个品种按新分类仿制申请获批并视同过评，40个品种按存量品种一致性评价补充申请过评。其中，21个品种为首家过评，丙酸氟替卡松鼻喷雾剂、布地奈德福莫特罗吸入气雾剂(Ⅰ)/(Ⅱ)、萘普生钠软胶囊、瑞舒伐他汀依折麦布片(Ⅰ)、维生素K1滴剂、吸入用丙酸倍氯米松混悬液、硝酸甘油喷雾剂、熊去氧胆酸口服混悬液、盐酸伐地那非口崩片、盐酸拉贝洛尔氯化钠注射液、盐酸哌甲酯缓释片、注射用氟氧头孢钠、注射用头孢比罗酯钠等14个品种为首仿品种。2025年4月主要注册类型品种获批情况数据来源：米内网中国申报进度数据库（MED）、CDE、NMPA；相关统计字段按药品名称统计，申报企业数按主申报企业统计，时间截至2025年4月30日；获批品种按NMPA发布时间统计；药物作用靶点以及适应症整理自公开资料；首仿品种指中国内地首仿品种。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2025-04-30

·摩熵医药

24款！4月首家过评品种大盘点

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。医药圈的4月，迎来一波首家过评药品的“小高潮”，这些药品不仅突破技术壁垒，更有望改写市场格局。根据摩熵医药数据库，本月倍特药业、福元医药、立方制药等22家企业的24款药品（按批文号计）首家过评，共23个品种。014月首家过评药品清单截图来源：摩熵医药数据库，整理自摩熵咨询02单品分析01熊去氧胆酸口服混悬液4月8日，成都赛璟生物研发的熊去氧胆酸口服混悬液作为国内首仿3.1类新药，正式获批上市。该药品是国内企业首个且唯一获批治疗罕见病囊性纤维化相关肝病（CFALD）的药物，填补了国内目前上市的熊去氧胆酸片剂/胶囊剂无此适应症的空白。熊去氧胆酸是一种外源性胆酸药物，通过补充机体缺乏的胆酸，从而调节胆固醇代谢和胆汁的胆碱酸（胆酸的代谢产物）浓度，改善胆汁分泌功能。它主要通过在肝脏中增加胆汁酸的合成和排泄，促进胆盐的肠道循环，从而降低胆固醇的吸收。据摩熵医药-销售数据库显示，2023年熊去氧胆酸全国医院端销售额达25.84亿元，由于纳入集采原因，2024年销售额受到较大影响，2024上半年销售额8.84亿元。截图来源：摩熵医药全国医院（全终端）销售数据库成都赛璟生物获批的熊去氧胆酸口服混悬液，相较于传统的片剂和胶囊剂，更符合儿童生理特征，适用于儿童和吞咽困难的患者，为临床用药提供了更佳的选择。02吸入用丙酸倍氯米松混悬液4月8日，江西艾施特制药的哮喘治疗用药吸入用丙酸倍氯米松混悬液获批上市，该药由济民可信集团创新技术药物研究院研发，江西艾施特制药有限公司落地生产。研究表明，吸入性糖皮质激素可显著降低急性发作风险，当前已成为哮喘长期控制的核心药物。吸入用丙酸倍氯米松混悬液作为国际公认的高效局部抗炎糖皮质激素（ICS），其原研药由意大利凯西制药开发，通过雾化吸入直接作用于气道，可有效控制炎症、缓解症状，并减少全身性激素副作用。哮喘是一种常见的慢性炎症性气道疾病，症状严重时可出现呼吸困难和低氧血症，临床亟需高效、安全的吸入制剂以改善患者预后。据摩熵医药-销售数据库显示，阻塞性气管疾病用药2023年全国医院端销售额达233.12亿元，2024上半年销售额119.95亿元。截图来源：摩熵医药全国医院（全终端）销售数据库此次江西艾施特制药的吸入用丙酸倍氯米松混悬液国内首仿上市，将为国内哮喘患者提供高效、安全的治疗新选择，为基层医疗机构和儿童患者提供更便捷的治疗方案，并有助于降低我国对哮喘药物的进口依赖。END本文为原创文章，转载请留言获取授权近期热门资源获取数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-2025042023H2-2024H1中国药品分析报告-2025042024年中国1类新药靶点白皮书-202503中国AI医疗健康企业创新发展百强榜单-202502解码护肤抗衰：消费偏好洞察与市场格局分析-2025022024年FDA批准上市的新药分析报告-2025012024年NMPA批准上市的新药分析报告-2025012024年医保谈判及市场分析报告-2025.012024年中国医疗健康投融资全景洞察报告-202501小分子化药白皮书（上）-2025012024医美注射材料市场发展分析报告-202412中国放射性药物产业白皮书-202410近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准

100 项与二丙酸倍氯米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00689	二丙酸倍氯米松	D07AC15 R03BA01 R01AD01	DB00394

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
季节性过敏性鼻炎	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2012-03-23
血管舒缩性鼻炎	日本	Sumitomo Pharmaceuticals Co., Ltd.	1999-10-01
哮喘	美国	Schering Corp.	1976-05-12
过敏性鼻炎	美国	Schering Corp.	1976-05-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性阻塞性肺疾病	临床3期	中国	CHIESI Farmaceutici SpA	2018-07-30
急性鼻窦炎	临床3期	意大利	CHIESI Farmaceutici SpA	2013-01-01
常年性鼻炎	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2010-05-01
哮吼	临床3期	意大利	CHIESI Farmaceutici SpA	2010-04-01
急性移植物抗宿主病	临床3期	美国	Soligenix, Inc.	2009-10-01
常年性变应性鼻炎	临床3期	美国	Teva Pharmaceutical Industries Ltd.	2009-10-01
持续性哮喘	临床3期	奥地利	CHIESI Farmaceutici SpA	2002-08-01
持续性哮喘	临床3期	意大利	CHIESI Farmaceutici SpA	2002-08-01
持续性哮喘	临床3期	波兰	CHIESI Farmaceutici SpA	2002-08-01
持续性哮喘	临床3期	西班牙	CHIESI Farmaceutici SpA	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04294641 (CTgov)	临床2期	慢性移植物抗宿主病	10	Ibrutinib	廠衊蓋膚齋網膚鹹齋壓 = 襯壓獵構範鏇襯獵鹹糧簾網憲餘醖選夢願艱廠 (淵鹹網窪鑰顧築淵觸願, 蓋構鬱醖構夢鑰顧獵壓 ~ 襯醖選觸窪願艱顧夢選) 更多	-	2025-01-22
ACAAI2024	N/A	猫过敏（疾病） FeNO	7	Ciclesonide MDI	製憲顧壓積範鹹淵醖鏇(鏇獵艱醖觸齋鹽鏇鬱齋) = 鹹淵觸鬱廠壓糧襯蓋廠鏇齋鏇選鏇築遞夢觸範 (齋繭築艱積夢網鹽膚顧, 32.9 ~ 186)	积极	2024-10-24
NCT03886441 (ESMO2024) 人工标引	临床2期	局部晚期非小细胞肺癌	292	Belomethason propionate inhalation	製選窪夢艱鹹構繭膚壓(齋膚範夢餘艱壓範鏇觸) = 壓簾壓艱憲鏇鏇糧範廠鏇遞網鬱壓蓋鹽齋艱鏇 (鏇鏇鏇製製鬱淵製構獵 ) 更多	积极	2024-09-16
				belomethason propionate inhalation (Control (no inhalation))	製選窪夢艱鹹構繭膚壓(齋膚範夢餘艱壓範鏇觸) = 夢網築繭鑰積鹹願齋構鏇遞網鬱壓蓋鹽齋艱鏇 (鏇鏇鏇製製鬱淵製構獵 ) 更多
NCT02517099 (PrIGMa, CTgov)	临床2期	哮喘 \| 炎症 \| 感染	60	Beclometasone+Azithromycin+Co-amoxiclav (Pathological Phenotype)	鹽簾範築膚遞遞獵製簾(鬱願憲鑰獵廠鹹鏇築構) = 願範鹹壓構餘繭觸簾製艱廠餘淵顧選網醖襯遞 (醖網築願願製膚淵憲鑰, 淵糧餘鬱鹹觸選壓糧窪 ~ 壓網蓋夢製衊衊構鹹鏇) 更多	-	2023-03-06
				Beclometasone+Azithromycin+Co-amoxiclav (Clinical Guidelines)	鹽簾範築膚遞遞獵製簾(鬱願憲鑰獵廠鹹鏇築構) = 網鹹鏇窪繭鏇廠願觸範艱廠餘淵顧選網醖襯遞 (醖網築願願製膚淵憲鑰, 壓夢艱膚積膚鏇齋憲積 ~ 糧糧蓋觸簾鑰窪遞選選) 更多
NCT02351180 (CTgov)	临床1/2期	肺移植排斥反应 \| 病毒性呼吸道感染	16	Inhaled beclomethasone (Inhaled Beclomethasone)	遞製遞艱願製願獵廠襯 = 範鏇淵鏇製鏇選遞膚遞範構積醖築憲糧繭鬱鑰 (窪醖襯繭鹽膚選鹹衊襯, 築淵願廠鏇獵糧鏇鹹鹹 ~ 選願築艱衊襯範簾憲糧) 更多	-	2022-03-03
				Placebo (Placebo)	遞製遞艱願製願獵廠襯 = 艱襯網壓網網鑰遞膚鹽範構積醖築憲糧繭鬱鑰 (窪醖襯繭鹽膚選鹹衊襯, 積淵鑰簾衊窪鑰觸憲鹹 ~ 築範膚簾廠鏇選膚願網) 更多
ATS2021	N/A	慢性阻塞性肺疾病	-	BDP/FF/GB 400/24/50 µg/d	夢簾糧艱築餘淵範繭鑰(廠蓋築顧餘積齋夢顧齋) = 築糧鹹夢積網製構衊鏇鬱夢網範糧醖醖鬱襯蓋 (膚壓膚選膚壓鬱餘餘憲 )	-	2021-05-03
				BDP/FF 400/24 µg/d	夢簾糧艱築餘淵範繭鑰(廠蓋築顧餘積齋夢顧齋) = 憲築夢積鑰齋鏇簾鹹膚鬱夢網範糧醖醖鬱襯蓋 (膚壓膚選膚壓鬱餘餘憲 )
NCT01584492 (Pubmed \| Eur J Pediatr)	临床2期	哮喘	56	CHF1535 (BDP 50 μg/FF 6 μg)	憲衊築廠餘網壓獵壓構(鏇願蓋構窪範範淵鹽齋) = 衊齋繭淵願衊鹹鬱醖窪構鬱壓選網夢壓糧鏇醖 (鹹獵蓋願鏇繭夢醖獵膚 )	-	2021-01-06
				Free combination BDP/FF	憲衊築廠餘網壓獵壓構(鏇願蓋構窪範範淵鹽齋) = 艱遞齋壓糧夢艱製鹹齋構鬱壓選網夢壓糧鏇醖 (鹹獵蓋願鏇繭夢醖獵膚 )
NCT01852513 (CTgov)	临床4期	季节性过敏性鼻炎	39	QNASL (QNASL Nasal Spray)	蓋醖選觸窪鏇選鬱壓淵(鑰範膚壓鏇網鏇鹹鏇鹹) = 廠糧網艱遞製繭壓蓋願膚艱製艱窪鏇選齋網獵 (選鹹衊簾鏇淵鑰製糧繭, 43.2) 更多	-	2020-10-09
				Placebo nasal spray (Placebo Nasal Spray)	蓋醖選觸窪鏇選鬱壓淵(鑰範膚壓鏇網鏇鹹鏇鹹) = 夢網窪夢窪糧顧壓獵艱膚艱製艱窪鏇選齋網獵 (選鹹衊簾鏇淵鑰製糧繭, 34.3) 更多
NCT02499887 (CTgov)	N/A	慢性阻塞性肺疾病 \| 哮喘	6	prednisone+albuterol (Standard of Care)	製餘窪淵鑰夢淵築製製(窪憲糧襯築夢積餘鑰糧) = 築憲糧築範鹹範選範齋蓋選襯鬱願選糧憲淵淵 (憲積衊襯憲築鬱觸廠築, 鹽醖鹹廠鹽膚廠網範獵 ~ 膚選願衊壓構遞鹹鑰壓) 更多	-	2019-06-04
				beclamethasone dipropionate+prednisone+albuterol (Treatment)	製餘窪淵鑰夢淵築製製(窪憲糧襯築夢積餘鑰糧) = 願選襯範遞範構夢簾製蓋選襯鬱願選糧憲淵淵 (憲積衊襯憲築鬱觸廠築, 壓構簾鹽繭蓋艱齋衊蓋 ~ 齋網簾夢蓋醖醖築壓鬱) 更多